PHILADELPHIA — For years, the common narrative in human developmental neuroimaging has been that gray matter in the brain – the tissue found in regions of the brain responsible for muscle control, sensory perception such as seeing and hearing, memory, emotions, speech, decision making, and self-control – declines in adolescence, a finding derived mainly from studies of gray matter volume and cortical thickness (the thickness of the outer layers of brain that contain gray matter). Since it has been well-established that larger brain volume is associated with better cognitive performance, it was puzzling that cognitive performance shows a dramatic improvement from childhood to young adulthood at the same time that brain volume and cortical thickness decline.
A new study published by Penn Medicine researchers this month and featured on the cover of the Journal of Neuroscience may help resolve this puzzle, revealing that while volume indeed decreases from childhood to young adulthood, gray matter density actually increases. Their findings also show that while females have lower brain volume, proportionate to their smaller size, they have higher gray matter density than males, which could explain why their cognitive performance is comparable despite having lower brain volume. Thus, while adolescents lose brain volume, and females have lower brain volume than males, this is compensated for by increased density of gray matter.
“It is quite rare for a single study to solve a paradox that has been lingering in a field for decades, let alone two paradoxes, as was done by Gennatas in his analysis of data from this large-scale study of a whole cohort of youths,” said Ruben Gur.
“We now have a richer, fuller concept of what happens during brain development and now better understand the complementary unfolding processes in the brain that describe what happens.”
The study was led by Ruben Gur, PhD, professor of Psychiatry, Neurology, and Radiology in the Perelman School of Medicine at the University of Pennsylvania, Raquel Gur, MD, PhD, a professor of Psychiatry, Neurology, and Radiology, and Efstathios Gennatas, MBBS, a doctoral student of neuroscience working in the Brain Behavior Laboratory at Penn.
According to Gur, the study findings may better explain the extent and intensity of changes in mental life and behavior that occur during the transition from childhood to young adulthood.
“If we are puzzled by the behavior of adolescents, it may help to know that they need to adjust to a brain that is changing in its size and composition at the same time that demands on performance and acceptable behavior keep scaling up,” Gur added.
In the study, the researchers evaluated 1,189 youth between the ages of 8 and 23 who completed magnetic resonance imaging as part of the Philadelphia Neurodevelopmental Cohort, a community-based study of brain development that includes rich neuroimaging and cognitive data, to look at age-related effects on multiple measures of regional gray matter, including gray matter volume, gray matter density, and cortical thickness. Neuroimaging allowed the researchers to derive several measures of human brain structure in a noninvasive way. Observing such measures during development allowed the researchers to study the brain at different ages to characterize how a child’s brain differs from an adult’s.
“This novel characterization of brain development may help us better understand the relationship between brain structure and cognitive performance,” Gennatas said.
“Our findings also emphasize the need to examine several measures of brain structure at the same time. Volume and cortical thickness have received the most attention in developmental studies in the past, but gray matter density may be as important for understanding how improved performance relates to brain development.”
Further study is required to fully characterize the biological underpinnings of different MRI-derived measures by combining neuroimaging and brain histology. The study’s findings in healthy people can also help researchers understand the effects of brain disorders in males and females as they evolve during adolescence.
Other Penn Medicine investigators involved in the study include Brian B. Avants, Daniel H. Wolf MD, PhD, Theodore Satterthwaite, MD, Kosha Ruparel, MSE, Rastko Ciric, and Hakon Hakonarson, MD, PhD.
This work was supported by the National Institutes of Health (NIH) grants (MH107235), (MH089983), (MH096891), and the Dowshen Neuroscience fund.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.